Drug · CHEMBL409

BICALUTAMIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. BICALUTAMIDE. Drugs and targets, record CHEMBL409. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL409

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: BICALUTAMIDE; ChEMBL
ChEMBL ID: CHEMBL409; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Calutide, Casodex, Cosudex, Kalumid; ChEMBL
Other names: Bicalutamida, ICI 176,334, ICI-176334, ICI176,334-1, NSC-759816; ChEMBL
DrugBank: DB01128; DrugBank
InChIKey: LKJPYSCBVHEWIU-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 33 diseases, from ATC, DailyMed and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
AR	Androgen receptor	Androgen Receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/367

Source ChEMBL

Diseases33

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
prostate cancer	Approval	TTD	130	129	https://conductscience.org/library/drugs?q=MONDO_0008315
prostate adenocarcinoma	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0005082
breast cancer	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0007254
triple-negative breast carcinoma	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0005494
COVID-19	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0100096
lower urinary tract symptom	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0008008
non-alcoholic fatty liver	Phase 1	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_1001248
polycystic ovary syndrome	Phase 1	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0008487
salivary duct carcinoma	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0044915
salivary gland cancer	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0004669

1 to 10 of 33Source Open Targets

See all 33 diseases

Trials184

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00002651	SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer	Phase 3	3,040	2017-04-17	bicalutamide	Its name	ClinicalTrials.gov
NCT00567580	Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer	Phase 3	1,792	2021-03-02	bicalutamide	Its name	ClinicalTrials.gov
NCT00005044	Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer	Phase 3	1,579	2017-10-31	bicalutamide	Its name	ClinicalTrials.gov
NCT00936390	Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer	Phase 3	1,538	2022-10-06	bicalutamide	Its name	ClinicalTrials.gov
NCT01809691	S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer	Phase 3	1,313	2022-09-08	bicalutamide	Its name	ClinicalTrials.gov
NCT00004124	S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer	Phase 3	983	2018-09-04	bicalutamide	Its name	ClinicalTrials.gov
NCT00002874	Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy	Phase 3	840	2017-08-18	bicalutamide	Its name	ClinicalTrials.gov
NCT00288080	Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer	Phase 3	612	2017-01-23	bicalutamide	Its name	ClinicalTrials.gov
NCT00004054	Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer	Phase 3	397	2015-01-07	bicalutamide	Its name	ClinicalTrials.gov
NCT01664923	Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer	Phase 2	396	2016-05-23	bicalutamide	Its name	ClinicalTrials.gov

1 to 10 of 184

See all 184 trials

Comparisons in its trials59

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: deaths from any cause	119 of 750	100 of 742	1,492	NCT00936390	Trial comparisons
TAS x 8 Weeks vs TAS x 28 Weeks: serious adverse events	121 of 747	109 of 735	1,482	NCT00005044	Trial comparisons
Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: Number of Participants With Acute Adverse Events	152 of 733	504 of 725	1,458	NCT00936390	Trial comparisons
Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: serious adverse events	20 of 733	33 of 725	1,458	NCT00936390	Trial comparisons
Continuous Hormonal Therapy vs Intermittent Hormonal Therapy: serious adverse events	19 of 732	10 of 702	1,434	NCT00002651	Trial comparisons
LHRHa + TAK-700 vs LHRHa + Bicalutamide: deaths from any cause	251 of 638	274 of 641	1,279	NCT01809691	Trial comparisons
LHRHa + TAK-700 vs LHRHa + Bicalutamide: serious adverse events	235 of 627	15 of 629	1,256	NCT01809691	Trial comparisons
Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: deaths from any cause	85 of 469	91 of 460	929	NCT00004124	Trial comparisons
Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: serious adverse events	3 of 469	11 of 460	929	NCT00004124	Trial comparisons
Bicalutamide vs Placebo: PSA Complete Response at End of Protocol Treatment	360 of 384	259 of 376	760	NCT00002874	Trial comparisons

1 to 10 of 59

See all 59 comparisons in its trials

Papers from its trials88

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35810050	RESULT	1	PubMed
35079115	RESULT	1	PubMed
33002431	RESULT	1	PubMed
33002429	RESULT	1	PubMed
28146658	RESULT	1	PubMed
26209502	RESULT	1	PubMed
25534388	RESULT	1	PubMed
24323034	RESULT	1	PubMed
23921574	RESULT	1	PubMed
23258223	RESULT	1	PubMed

1 to 10 of 88

See all 88 papers from its trials

Tests in its trials4

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Trail Making Test A	1	ConductCognition
Trail Making Test B	1	ConductCognition
Verbal Fluency	1	ConductCognition
Verbal Learning	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL409

GET https://conductscience.org/api/drugs/v1/CHEMBL409/diseases?page=2

API reference For AI assistants